Linshom Receives SBIR Phase II Contract Award from the United States Air Force for Its Dual Purpose Respiratory Device
Baltimore, MD, April 27, 2021 --(PR.com)-- Linshom announced today receipt of a phase II SBIR contract award with the United States Air Force (USAF) to fund ongoing development and deployment of the Linshom Predictive Continuous Respiratory Monitoring (LPCRM) System.
The $748K contract follows successful completion of a SBIR phase 1 award last year and funds more than a dozen milestones over twelve months. This funding will further advance the sensor, software and monitor technology for manufacturing and delivery to the DOD.
Lack of comprehensive, portable and inexpensive continuous respiratory monitoring at the patient’s bedside is a major gap in clinical care as the vast majority (75%) of complications have a respiratory component. Linshom is first to practically deliver a respiratory profile to the patient bedside that includes respiratory rate (RR), tidal volume (rTV), inspiratory / expiratory ratio (I/E), minute ventilation (rMV), and rapid-shallow breathing index (RSBI).
Dual purpose refers to the Air Force program’s focus on devices that can be commercialized in both the private and public (government) sectors. Beyond traditional clinical care use, the USAF will also be looking at battlefield uses such as medical evacuation and transport. The Linshom signal is not affected by motion artifact, temperature changes, humidity, or supplemental oxygen administration. This provides a unique match for use in demanding environments.
“This non-dilutive funding complements our current raise of a $3M series A round,” says Linshom CEO Richard Hughen. “We look forward to putting our FDA cleared device to use in Air Force sites later this year.”
About Linshom:
Linshom is an early stage, privately held, start-up company developing the first predictive, continuous respiratory monitoring system able to practically reach the patients’ bedside.
Contact:
Richard Hughen – CEO
RHughen@LinshomForLife.com
443.994.1448
The $748K contract follows successful completion of a SBIR phase 1 award last year and funds more than a dozen milestones over twelve months. This funding will further advance the sensor, software and monitor technology for manufacturing and delivery to the DOD.
Lack of comprehensive, portable and inexpensive continuous respiratory monitoring at the patient’s bedside is a major gap in clinical care as the vast majority (75%) of complications have a respiratory component. Linshom is first to practically deliver a respiratory profile to the patient bedside that includes respiratory rate (RR), tidal volume (rTV), inspiratory / expiratory ratio (I/E), minute ventilation (rMV), and rapid-shallow breathing index (RSBI).
Dual purpose refers to the Air Force program’s focus on devices that can be commercialized in both the private and public (government) sectors. Beyond traditional clinical care use, the USAF will also be looking at battlefield uses such as medical evacuation and transport. The Linshom signal is not affected by motion artifact, temperature changes, humidity, or supplemental oxygen administration. This provides a unique match for use in demanding environments.
“This non-dilutive funding complements our current raise of a $3M series A round,” says Linshom CEO Richard Hughen. “We look forward to putting our FDA cleared device to use in Air Force sites later this year.”
About Linshom:
Linshom is an early stage, privately held, start-up company developing the first predictive, continuous respiratory monitoring system able to practically reach the patients’ bedside.
Contact:
Richard Hughen – CEO
RHughen@LinshomForLife.com
443.994.1448
Contact
Linshom
Richard Hughen
443-994-1448
www.linshomforlife.com
Richard Hughen
443-994-1448
www.linshomforlife.com
Contact
Categories